Alkermes Plc. (ALKS) Stock Price & Analysis

Alkermes Plc. (ALKS) rose 4.33% to USD 44.29 as of June 10, 2026 at 02:15 UTC, according to Nexqual real-time market data.

ALKS last closed at USD 42.45; the session ranged USD 43.03–44.93 on volume of 2,488,343 shares. Market capitalization is $7.38B, with a 52-week range of USD 25.17–44.93 (NMS). Source: Nexqual, June 10, 2026 at 02:15 UTC.

Key Statistics (as of June 10, 2026 at 02:15 UTC)

Technical Analysis (ALKS)

Nexqual's technical model rates ALKS "BUY" based on 5 bullish and 2 bearish signals across 124 daily candles, as of June 10, 2026 at 02:15 UTC.

Analyst Ratings (ALKS)

Wall Street analysts rate ALKS "Buy" based on 16 analysts, with a mean price target of USD 46.13 (range USD 34–59), per Nexqual as of June 10, 2026 at 02:15 UTC.

Earnings (ALKS)

Recent Earnings History

Source: Nexqual, June 10, 2026 at 02:15 UTC.

Financials & Fundamentals (ALKS)

Source: Nexqual, June 10, 2026 at 02:15 UTC.

Financial Health Score (ALKS)

Nexqual rates Alkermes Plc.'s overall financial health "Mixed" across five dimensions, as of June 10, 2026 at 02:15 UTC.

Ownership (ALKS)

Source: Nexqual, June 10, 2026 at 02:15 UTC.

Leadership (ALKS)

Alkermes Plc. is led by Richard F. Pops (age 63), Chairman & CEO, per Nexqual as of June 10, 2026 at 02:15 UTC.

Major Backers & Investors (ALKS)

Notable institutional backers of Alkermes Plc. include Baker Bros. Advisors, LP, American Century Companies Inc, Renaissance Technologies, according to Nexqual as of June 10, 2026 at 02:15 UTC.

Active Investors

Index Funds (Passive)

Source: Nexqual, June 10, 2026 at 02:15 UTC.

From Alkermes Plc.'s Latest SEC 10-K Filing (filed 2026-02-25)

Key Strengths & Strategy (as disclosed to the SEC)

• Proprietary Technology Platforms We have used our proprietary technology platforms, which include technologies owned and exclusively licensed to us, to establish drug development, clinical development and regulatory expertise and in the development of our products.
• We purchase LUMRYZ API and outsource the manufacturing of LUMRYZ drug product to several contract manufacturers in the U.S. and outside of the U.S.
• In such cases, our licensee usually holds the relevant marketing authorization from the FDA or other relevant regulatory authority, and we support this authorization as needed, including by furnishing a copy of the product's Drug Master File, or chemistry, manufacturing and controls data, to the relevant regulator.
• We have a proprietary portfolio of patent rights and exclusive licenses to patents and patent applications, which includes numerous patents in the U.S. and in other countries directed to compositions of matter, methods of treatment and formulations, and processes of preparation.

Partnerships

• Janssen INVEGA SUSTENNA/XEPLION, INVEGA TRINZA/TREVICTA and INVEGA HAFYERA/BYANNLI Under an exclusive license agreement with Janssen, we provided Janssen with rights to, and know-how, training and technical assistance in respect of, our small particle pharmaceutical compound technology, known as NANOCRYSTAL technology, which was used to develop the long-acting INVEGA products, and we received milestone payments from Janssen upon the achievement of certain development goals.
• Pursuant to the settlement and license agreement entered into between Jazz and Avadel in October 2025 (the "Avadel Settlement Agreement"), from October 1, 2025, Jazz receives a royalty of 3.85% (subject to certain adjustments set forth in the agreement) on net sales of LUMRYZ sold for narcolepsy and additional royalties on net sales of LUMRYZ sold for any other future FDA-approved non-narcolepsy indications.

Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.

Peers & Related Stocks

Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 02:15 UTC. This page is informational and not investment advice.